nobiletin has been researched along with Osteogenic Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farkas, ME; Harrington, ME; Labriola, C; Lellupitiyage Don, SS; Lin, HH; Robertson, KL; Taylor, SR | 1 |
| Cheng, HL; Hsieh, MJ; Lin, CW; Lu, KH; Lue, KH; Yang, JS; Yang, SF | 1 |
2 other study(ies) available for nobiletin and Osteogenic Sarcoma
| Article | Year |
|---|---|
Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-dependent manner.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Circadian Rhythm; Flavones; Humans; Osteosarcoma | 2020 |
Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Flavones; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Osteosarcoma | 2016 |